The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Psilocybin

Brief Summary

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder

Intervention / Treatment

  • Drug: Psilocybin

Condition or Disease

  • Post Traumatic Stress Disorder

Phase

Study Design

Study type: Interventional
Status: Recruiting
Study results: No Results Available
Age: 18 Years and older   (Adult, Older Adult)
Enrollment: 20 ()
Funded by: Industry

Masking

Clinical Trial Dates

Start date: Jun 01, 2022
Primary Completion: Jun 01, 2023
Completion Date: Aug 01, 2023
Study First Posted: Apr 05, 2022
Last Updated: May 20, 2022

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder

Eligibility Criteria

Sex: All

This clinical trial is recruiting

Are you interested in participating in this trial or others? We'd love to help.

More Details

NCT Number: NCT05312151
Other IDs: COMP201
Study URL: https://ClinicalTrials.gov/show/NCT05312151
Last updated: Jun 17, 2022